Abstract
Introduction
Neurodegeneration with brain iron accumulation (NBIA) encompasses a group of rare neurodegenerative diseases characterized by relentlessly progressive extrapyramidal signs and iron accumulation in the brain usually in the globus pallidus. 1, 2 The most prevalent form of NBIA is pantothenate kinase associated neurodegeneration (PKAN) also known as NBIA-1 which accounts for approximately half of the cases of NBIA. 3 This syndrome first described by Julius Hallervorden and Hugo Spatz in 1922; 4 however, their involvement with Nazi extermination politics lead to discredit them. 5 PKAN syndrome is characterized by autosomal recessive inheritance and the 'eye of the tiger' pattern of iron accumulation in the pallidum on T2 weighted magnetic resonance imaging (MRI) which is caused by iron deposition in the periphery (hypointensity) and necrosis on its core (hyperintensity). 6, 7 Clinical presentations include dystonia, dysarthria, and dysphasia. Dementia, severe mental retardation and severe movement disability may develop at later stages. 8 10 In the current study, we report clinical and genetic findings of three PKAN patients from an Iranian family.
Materials and Methods
Three sibling patients were diagnosed based on clinical presentations especially extrapyramidal signs and brain MRI findings of iron deposition in the globus pallidus. Details of clinical information and familial reputation (hisotor and information) were obtained and blood samples were collected from all patients after they had given informed consent. This research was performed in accordance with the Declaration of Helsinki and with approval of the ethics board of the University of Tehran. Participants or their guardians consented to participate after being informed of the nature of the research.
Primers were designed to amplify all eight exons. The exons and flanking intronic sequences of PANK2 were amplified from DNA of leukocytes of the affected individuals. Amplicons were sequenced using the ABI Big Dye terminator chemistry and an ABI Prism 3700 instrument (Applied Biosystems, Foster City, CA). Sequences were analyzed with the Sequencher software (Gene Codes Corporation, Ann Arbor, MI). Obtained DNA sequences were compared to NG_008131.1, NM_024960.4, and NP_705902.2. To determin the extent of amino acids conservation and the effect of DNA variations, we attained homologous proteins amino acid sequences of other species from ENSEMBL (http://www.ensembl.org/index.html) and aligned using the ClustalW2.0 software (http://www.ebi.ac.uk/Tools/msa/clustalw2/).
Results
PANK2 mutation was found in all three patients. Patients born to consanguineous family with no familial history of neurological disease and had homozygous mutations in PANK2 gene. All these three patients had eye-of-the-tiger signs in T2 weighed brain MRI (Fig. 1) .
Case I was 24 years old and suffered from progressive dystonia. He was normal at birth and during early developmental periods. At the age 10, he complained from stiffness in his hands and 2 years later dystonia appeared in his upper limbs. Oromandibular dystonia caused problems in feeding. On exam he had severe dysarthria, dystonia (more prominent in hands and oromandibular region), Babinski sign and tremor in hands. Case II was 18 years old girl and at the age of 10 her parents noticed stiffness and resting tremor in his upper and later in lower limbs and poor balance in usual movements and progressive difficulty in walking. She had severe hand dystonia and orolingual dystonia with recurrent lips and tongue biting. She could not walk without aid and was dependent for all daily living activities.
Case III was a 17 years old boy with normal early development. At the age 9, dystonia appeared in upper limbs. One year later, dysarthria, dysphasia and gait disturbance were added to the symptoms. Pursuit eye movements were fragmented and the saccades were slow.
All three patients were found to be homozygous for a mutation in exon 3 of the gene which resulted in a change of arginine to tryptophan at amino acid position 357 in pantothenate kinase2 enzyme (Fig. 2) . This mutation have been previously reported by Zhou et al. 9 Importantly, this amino acid position is completely http://ijnl.tums.ac.ir 5 October conserved in homologous proteins (Table 1 ). 
Discussion
There are evidences for the existence of an isoform of PANK2 in mitochondrial in which the disease is caused by loss of function of this isoform. 10, 11 The PANK2 gene expresses abundantly in the brain. 9 It is predicted that the preprotein has 29 amino acid mitochondrial target sequence at the amino terminus. 11 Pantothenate kinase enzyme catalyzes the first and the most important rate controlling step of coenzyme A biosynthesis by phosphorylation of pantothenate (vitamin B5) to phosphopantothenate which is rapidly enter in the coenzyme A biosynthesis. 12 In its acetyl form, coenzyme A contributes in tricarboxylic acid cycle and fatty acids beta oxidation as an acyl carrier. In the backward feedback coenzyme A and its thioester form can inhibit pantothenate kinase by binding to ATP binding site of the enzyme. 13 The exact pathogenic mechanisms of the disease are unknown, but it has been suggested that stop production of phosphopantothenate causes accumulation of cysteine at the later stage of coenzyme A production and this surplus mass of cysteine can cause accumulation of excess iron in the brain and tissue damage by promoting oxidative stress. 9, 14 In this study, we identified three siblings affected with PKAN; all of them had mutations in PANK2 gene. On brain MR imaging of all patients with
